INT3405

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.71
First Reported 1978
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 8.89
Pain Relevance 4.02

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (BCAR1) cytosol (BCAR1) signal transduction (BCAR1)
cell adhesion (BCAR1) plasma membrane (BCAR1) cell division (BCAR1)
Anatomy Link Frequency
neuronal 1
mitral valve 1
BCAR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 17 100.00 Very High Very High Very High
cva 11 100.00 Very High Very High Very High
Catecholamine 7 100.00 Very High Very High Very High
Analgesic 16 99.64 Very High Very High Very High
cINOD 20 99.04 Very High Very High Very High
Paracetamol 29 98.86 Very High Very High Very High
dexamethasone 6 98.84 Very High Very High Very High
carbamazepine 34 98.52 Very High Very High Very High
Calcium channel 2 98.16 Very High Very High Very High
diclofenac 48 98.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cerebellar Ataxia 74 100.00 Very High Very High Very High
Coronary Artery Disease 52 100.00 Very High Very High Very High
Carotid Stenosis 34 100.00 Very High Very High Very High
Cv General 3 Under Development 15 100.00 Very High Very High Very High
Chromosome Aberrations 8 100.00 Very High Very High Very High
Cerebellar Diseases 18 99.26 Very High Very High Very High
INFLAMMATION 44 98.84 Very High Very High Very High
Mitral Valve Prolapse 5 97.84 Very High Very High Very High
Ulcers 8 97.34 Very High Very High Very High
Angina 10 94.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results suggest that dexamethasone does not act as a secretagogue but may be related to the synthesis of Met-enk and CAs.
Gene_expression (synthesis) of CAs associated with catecholamine and dexamethasone
1) Confidence 0.71 Published 1984 Journal Life Sci. Section Abstract Doc Link 6492996 Disease Relevance 0.23 Pain Relevance 0.73
Thus, symptomatic CAS induced by ergonovine was absent in the majority of these 24 patients with idiopathic mitral valve prolapse syndrome.
Neg (absent) Gene_expression (absent) of CAS in mitral valve associated with mitral valve prolapse and cva
2) Confidence 0.52 Published 1978 Journal Cathet Cardiovasc Diagn Section Abstract Doc Link 737730 Disease Relevance 1.56 Pain Relevance 0.92
Traditional CAs produce their effects through blockade of the L-type calcium channel.
Gene_expression (produce) of CAs associated with calcium channel and antagonist
3) Confidence 0.51 Published 1997 Journal Clin Ther Section Abstract Doc Link 9385501 Disease Relevance 0.17 Pain Relevance 0.48
Among men with median or higher work time, men with CAS consistently experienced substantially higher rates of IMT change than men without CAS across all exposure measures (Table 7).
Neg (without) Gene_expression (experienced) of CAS associated with carotid stenosis
4) Confidence 0.45 Published 2009 Journal Prev Chronic Dis Section Body Doc Link PMC2644586 Disease Relevance 0.86 Pain Relevance 0
Current regulations may not provide sufficient protection, especially for middle-aged workers with preexisting IHD or CAS.
Gene_expression (preexisting) of CAS associated with coronary artery disease and carotid stenosis
5) Confidence 0.45 Published 2009 Journal Prev Chronic Dis Section Body Doc Link PMC2644586 Disease Relevance 0.73 Pain Relevance 0
The phospho-Cas signals were normalized to total Cas protein content and expressed as a ratio of p-Cas/Cas.
Gene_expression (expressed) of Cas
6) Confidence 0.36 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2759504 Disease Relevance 0.23 Pain Relevance 0
The MBR was operated in parallel with the CAS process (aeration tank and secondary settling tank).
Gene_expression (operated) of CAS
7) Confidence 0.31 Published 2006 Journal Anal Bioanal Chem Section Body Doc Link PMC1805043 Disease Relevance 0 Pain Relevance 0
Fig. 1Removal, during MBR and CAS treatment, of the analgesics and anti-inflammatory drugs naproxen (a), ketoprofen (b), ibuprofen (c), mefenamic acid (d), diclofenac (e), indomethacin (f), acetaminophen (g), and propyphenazone (h)Fig. 2Removal during MBR and CAS treatment of the antibiotics ofloxacin (a), sulfamethoxazole (b), and erythromycin (c), the ?
Gene_expression (treatment) of CAS associated with paracetamol, inflammation, analgesic, cinod and diclofenac
8) Confidence 0.31 Published 2006 Journal Anal Bioanal Chem Section Body Doc Link PMC1805043 Disease Relevance 0.17 Pain Relevance 0.37
-blockers atenolol (d) and metoprolol (e), the anti-ulcer agent ranitidine (f), the antiepileptic drug carbamazepine (g), and the psychiatric drug paroxetine (h)Fig. 3Removal during MBR and CAS treatment of the lipid regulator and cholesterol-lowering statin drugs gemfibrozil (a), bezafibrate (b), clofibric acid (c), and pravastatin (d), the diuretic hydrochlorothiazide (e), and the hypoglycaemic agent glibenclamide (f)
Gene_expression (treatment) of CAS associated with ulcers and carbamazepine
9) Confidence 0.31 Published 2006 Journal Anal Bioanal Chem Section Body Doc Link PMC1805043 Disease Relevance 0.25 Pain Relevance 0.60
Fig. 1Removal, during MBR and CAS treatment, of the analgesics and anti-inflammatory drugs naproxen (a), ketoprofen (b), ibuprofen (c), mefenamic acid (d), diclofenac (e), indomethacin (f), acetaminophen (g), and propyphenazone (h)Fig. 2Removal during MBR and CAS treatment of the antibiotics ofloxacin (a), sulfamethoxazole (b), and erythromycin (c), the ?
Gene_expression (treatment) of CAS associated with paracetamol, inflammation, analgesic, cinod and diclofenac
10) Confidence 0.31 Published 2006 Journal Anal Bioanal Chem Section Body Doc Link PMC1805043 Disease Relevance 0.24 Pain Relevance 0.49
In contrast, if wild-type p53 mutates into mutant-type p53, cells with damaged DNA may enter the S phase prematurely and produce CAs (Vogelstein 1990).
Gene_expression (produce) of CAs associated with chromosome aberrations
11) Confidence 0.09 Published 2007 Journal Environ Health Perspect Section Body Doc Link PMC1852665 Disease Relevance 0.41 Pain Relevance 0
It should be pointed out that 4 barriers have hampered meaningful clinical trials [219]: the rarity of each cerebellar disorder considered alone, the heteregeneous presentation of CAs, the fact that a substantial degree of neuronal loss has already occurred when symptoms appear, and the absence of biomarkers.
Gene_expression (presentation) of CAs in neuronal associated with cerebellar diseases and cerebellar ataxia
12) Confidence 0.08 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2866461 Disease Relevance 2.05 Pain Relevance 0.07
However, some CAs do respond to specific therapies and should not be overlooked, such as AVED which responds to vitamin E supplements [160].
Gene_expression (respond) of CAs associated with cerebellar ataxia
13) Confidence 0.08 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2866461 Disease Relevance 1.63 Pain Relevance 0.04
HLA-DR expression before surgery in AAS and CAS patients was not significantly different from that measured in healthy volunteers.
Gene_expression (expression) of CAS
14) Confidence 0.06 Published 2010 Journal Crit Care Section Body Doc Link PMC2887183 Disease Relevance 0.36 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox